PharmaCyte Biotech (PMCB) Other Gross PP&E Adjustments (2016 - 2025)
PharmaCyte Biotech (PMCB) has disclosed Other Gross PP&E Adjustments for 11 consecutive years, with -$523822.0 as the latest value for Q2 2025.
- Quarterly Other Gross PP&E Adjustments fell 6.01% to -$523822.0 in Q2 2025 from the year-ago period, while the trailing twelve-month figure was -$523822.0 through Jan 2026, down 6.01% year-over-year, with the annual reading at -$523822.0 for FY2025, 6.01% down from the prior year.
- Other Gross PP&E Adjustments for Q2 2025 was -$523822.0 at PharmaCyte Biotech, down from -$494130.0 in the prior quarter.
- The five-year high for Other Gross PP&E Adjustments was -$369666.0 in Q2 2023, with the low at -$2.5 million in Q2 2021.
- Average Other Gross PP&E Adjustments over 5 years is -$903842.6, with a median of -$523822.0 recorded in 2025.
- The sharpest move saw Other Gross PP&E Adjustments soared 77.06% in 2022, then tumbled 33.67% in 2024.
- Over 5 years, Other Gross PP&E Adjustments stood at -$2.5 million in 2021, then skyrocketed by 77.06% to -$584321.0 in 2022, then surged by 36.74% to -$369666.0 in 2023, then plummeted by 33.67% to -$494130.0 in 2024, then decreased by 6.01% to -$523822.0 in 2025.
- According to Business Quant data, Other Gross PP&E Adjustments over the past three periods came in at -$523822.0, -$494130.0, and -$369666.0 for Q2 2025, Q2 2024, and Q2 2023 respectively.